ArticleOncoTargets and therapy2018

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway.

Hui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.